2019
Quantification of Neuropeptide Y and Four of Its Metabolites in Human Plasma by Micro-UHPLC-MS/MS
Vocat C, Dunand M, Hubers SA, Bourdillon N, Millet G, Brown NJ, Wuerzner G, Grouzmann E, Eugster PJ. Quantification of Neuropeptide Y and Four of Its Metabolites in Human Plasma by Micro-UHPLC-MS/MS. Analytical Chemistry 2019, 92: 859-866. PMID: 31790196, PMCID: PMC8541045, DOI: 10.1021/acs.analchem.9b03505.Peer-Reviewed Original ResearchConceptsNeuropeptide YNPY3-36Hypertensive patientsHealthy volunteersConcentrations of NPYEndogenous neuropeptide YHuman plasmaNPY2-36Pathological processesReference intervalsEndogenous peptidesChromatography-tandem mass spectrometryPatientsAcid peptideMS/MSVolunteersMetabolitesInter-assay precisionPeptidesPrototype peptideTandem mass spectrometryDistinct effectsOrthostasisCatecholaminesSubpicomolar concentrations
2013
An LC–MS assay for the screening of cardiovascular medications in human samples
Dias E, Hachey B, McNaughton C, Nian H, Yu C, Straka B, Brown NJ, Caprioli RM. An LC–MS assay for the screening of cardiovascular medications in human samples. Journal Of Chromatography B 2013, 937: 44-53. PMID: 24013190, PMCID: PMC3800555, DOI: 10.1016/j.jchromb.2013.08.010.Peer-Reviewed Original ResearchConceptsAngiotensin II receptor blockersDrug metabolitesCardiovascular drugsDrug classesHospitalized patientsSingle LC-MS/MS methodLC-MS assayLC-MS/MS methodII receptor blockersCalcium channel blockersCardiovascular drug classesClinical samplesDrug detectionSpiked samplesMS methodCardiovascular medicationsReceptor blockersBeta blockersMedication administrationChannel blockersEnzyme inhibitorsClinical settingBlockersDrugsSimultaneous analysis